Rachana focuses on assessing the efficacy of co-stimulation using agonist antibodies such as anti-GITR, and immune checkpoint blockade using antagonist antibodies against PD-1 and Lag3. Her interests lie in delineating the factors involved in the success and failure of these therapies; in particular the interactions between the tumor and its infiltrating lymphocytes.